Ishita Drugs & Industries Board of Directors

Get the latest insights into the leadership at Ishita Drugs & Industries. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Jagdish Agrawal Managing Director
Mrs. Abha Agrawal Director
Mr. Arvind Sapkal Director
Ms. Dhwani Solanki Director

Ishita Drugs & Industries Share price

ISHITADR

71.16

0.21 (-0.29%)
Last updated on 20 Feb, 2026 | 14:35 IST
alert_iconwatchlist_icon
BUYSELL
Today's High

71.16

Today's Low

71.15

52 Week Low

66.00

52 Week High

90.85

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Ishita Drugs & Industries FAQs

The board at Ishita Drugs & Industries consists of experienced professionals, including Mr. Jagdish Agrawal , Mrs. Abha Agrawal , and others, overseeing the company’s strategic and corporate governance.

Directors at Ishita Drugs & Industries are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Jagdish Agrawal is the current chairman at Ishita Drugs & Industries.

Executive directors at Ishita Drugs & Industries are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Ishita Drugs & Industries adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Ishita Drugs & Industries, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost